CargoTx

CARGO is a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for cancer patients. Terms:

[CargoTx @CARGOTx]

Today at #ASH24 we are introducing CRG-023, our tri-specific #CART-cell therapy product candidate. See how we are aiming to deliver multiple, therapeutically beneficial transgene “cargo” from a single vector with the potential to benefit cancer patients: https://t.co/gB1vmbkQd0

[CargoTx @CARGOTx]

We’re headed to #ASH24 to introduce CRG-023, our CD19/CD20/CD22 tri-specific CAR T developed using a tri-cistronic construct and designed with the goal of providing patients with a broad range of B-cell malignancies with durable, complete responses. Tune in to our CRG-023 presentation this weekend!

Learn More: https://t.co/8CHKlztHww

[CargoTx @CARGOTx]

Today we reported our Q3 2024 financial results and shared business updates, including 57 patients dosed with continued manufacturing success for our Phase 2 clinical study of firi-cel, and progress towards IND for our tri-specific #CART program CRG-023, as well as the appointment of our CFO, Anup Radhakrishnan as COO and CFO. Learn more: https://t.co/9o2leRTNUE #CRGX #celltherapy

[CargoTx @CARGOTx]

We’re proud to be part of the strong blood cancer community that came together on #LightTheNight to support The Leukemia & Lymphoma Society’s life-saving research for cancer patients.#celltherapy $CRGX

[CargoTx @CARGOTx]

#ASH24 is just a month away! We’ll be introducing CRG-023, our tri-specific #CART product candidate designed to provide more patients with a broad range of B-cell malignancies with durable responses. Encouraging preclinical data showed sustained, durable anti-B cell lymphoma activity. Read more: https://t.co/zpO2IFohVJ #celltherapy

[CargoTx @CARGOTx]

Today we reported our 2Q'24 financial results and provided a business update, highlighting continued execution of our potentially pivotal Phase 2 study for firi-cel and our tri-specific CAR T program, CRG-023. Learn more: https://t.co/LX605ulrXa $CRGX #celltherapy #CART

[CargoTx @CARGOTx]

Congratulations @StanfordMed investigators on @TheLancet publication of theirfavorable Phase 1 study evaluating our lead CD22 #CART #celltherapy firi-cel! Findings demonstrate curative potential and support our enrolling Phase 2 study. Learn more: https://t.co/CpX8QJQQzi

[CargoTx @CARGOTx]

We're thrilled to be featured in the 2024 New Era in Life Sciences Report published in @Newsweek and Investment Reports, which highlights recent innovations in the field, including our work to develop CAR T therapies for unmet patient needs: https://t.co/34S1GU05xr #celltherapy #CART

[CargoTx @CARGOTx]

Join CARGO’s President and CEO Gina Chapman for a fireside chat at the @Jefferies Global Healthcare Conference in New York, on June 5 at 11:30 a.m. EST, where she will share our latest company highlights. Learn more: https://t.co/saYVfBzYiF $CRGX #CART #JefferiesHealthcare

[CargoTx @CARGOTx]

We’re pleased to welcome Jane Pritchett Henderson to our Board of Directors, adding strategic finance and broad biotech operating experience as we continue to execute our potentially pivotal Phase 2 clinical study while advancing our CAR T pipeline. Learn more: https://t.co/hiReZEouSv #CART #celltherapy

[CargoTx @CARGOTx]

Today we announced a $110 million PIPE financing that will support BLA preparation for our potentially pivotal Phase 2 study FIRCE-1 of firi-cel and IND-enabling studies for CRG-023, our novel tri-specific #CART: https://t.co/bQmgocbi2k $CRGX #celltherapy

[CargoTx @CARGOTx]

We are proud to be named one of @BioSpace’s NextGen Class of 2024: Top Life Sciences Startups to Watch This Year! This recognition highlights our mission to deliver next-generation CAR T-cell therapies with curative potential: https://t.co/nuK1Rp14Uj #CART #celltherapy #oncology

[CargoTx @CARGOTx]

Impressive ongoing follow-up from Stanford’s Phase 1 study for CARGO’s firi-cel will be presented at the @EHA_Hematology #EHA2024 Congress in June. Learn more: https://t.co/w5KFxzfTPM
$CRGX #celltherapy #CART

[CargoTx @CARGOTx]

Today we reported our first quarter 2024 financial results and provided a business update, including progress on enrollment for our potentially pivotal Phase 2 clinical study for our lead #CART cell therapy candidate, firi-cel. Learn more: https://t.co/w5KFxzfTPM $CRGX

[CargoTx @CARGOTx]

We are celebrating the opening of our new headquarters in San Carlos, CA! This milestone signifies our progress in advancing our next-generation #CART pipeline and reflects our commitment to developing potential curative therapies for cancer patients #celltherapy #TeamCARGO

[CargoTx @CARGOTx]

Today, we announced the appointment of Kapil Dhingra, M.B.B.S., to our Board of Directors, adding #oncology and cell therapy clinical development expertise to our Board as we continue to advance our lead #CART cell therapy candidate: https://t.co/cCuifaMLgO

$CRGX #celltherapy

[CargoTx @CARGOTx]

Today we reported our fourth quarter and full year 2023 financial results and provided a business update. Learn more: https://t.co/uPaw5VM5FW
$CRGX #celltherapy #CART

[CargoTx @CARGOTx]

CARGO’s President and CEO Gina Chapman will participate in a corporate panel discussion on #celltherapy at the 44th Annual @TDCowen Healthcare Conference in Boston, MA, on March 6 at 9:10 am EST: https://t.co/daWypcUFfi $CRGX #CART